Tempus AI Stock Price, News & Analysis

Tempus AI (NASDAQ: TEM) announced the expansion of its AI-powered care pathway intelligence platform, Tempus Next, into breast cancer applications. The platform, which has already screened thousands of lung cancer patients since its 2024 launch, will now support five different biomarker testing gaps specific to breast cancer.

Mercy, with over 1,000 physician practice locations and more than 5,000 physicians, has integrated Tempus Next for both breast and lung cancer into its EMR system. The platform helps physicians stay current with evolving clinical guidelines by analyzing electronic medical records and identifying patients who may benefit from guideline-based suggestions.

Tempus AI (NASDAQ: TEM) has announced the pricing of $650 million aggregate principal amount of 0.75% Convertible Senior Notes due 2030 in a private placement, upsized from the previously announced $400 million. The company also granted an over-allotment option for an additional $100 million in notes.

The Notes will mature on July 15, 2030, with a 0.75% annual interest rate payable semiannually. The initial conversion rate is 11.8778 shares of Class A common stock per $1,000 principal amount, equivalent to a conversion price of approximately $84.19 per share, representing a 32.5% premium to the last reported sale price.

Tempus expects net proceeds of approximately $625.3 million (or $721.7 million if the over-allotment option is exercised), which will be used to repay $274.7 million of outstanding senior secured term loans, pay $36.2 million for capped call transactions, and fund general corporate purposes. The company has entered into capped call transactions to reduce potential dilution, with an initial cap price of $111.1950, representing a 75% premium over the last reported stock price.

[ "Successful upsizing of offering from $400M to $650M indicates strong investor interest", "Low interest rate of 0.75% on the convertible notes", "Net proceeds of $625.3M (potentially $721.7M with over-allotment) strengthen balance sheet", "Capped call transactions implemented to minimize potential dilution for existing shareholders", "Debt refinancing of $274.7M in senior secured term loans could improve capital structure" ]

Tempus AI (NASDAQ: TEM) has announced plans to offer $400 million in Convertible Senior Notes due 2030 through a private placement to qualified institutional buyers. The company will also grant initial purchasers an over-allotment option for an additional $60 million in notes.

The notes will be unsecured obligations maturing on July 15, 2030, with semiannual interest payments. Upon conversion, Tempus will have the flexibility to settle in cash, shares of Class A common stock, or a combination thereof. A significant portion of the proceeds will be used to repay $274.7 million in outstanding senior secured term loans.

To mitigate potential dilution, Tempus plans to enter into capped call transactions with financial institutions. These transactions are designed to reduce dilution of Class A common stock upon note conversion and/or offset cash payments exceeding the principal amount of converted notes.

Ambry Genetics, a subsidiary of Tempus AI (NASDAQ: TEM), has announced the validation of its CARE Program's accuracy in a peer-reviewed study published in the Journal of the National Comprehensive Cancer Network. The study demonstrates that CARE achieves 99.5% accuracy in interpreting NCCN Guidelines for hereditary cancer risk assessment, successfully identifying 398 out of 400 real-world patient cases.

The CARE Program is a HIPAA-compliant digital tool that integrates with electronic health records to assess patients' cancer risks through medical and family history collection. This system helps identify candidates for hereditary cancer testing and increased cancer screening, particularly important as approximately 5% of individuals have cancer predisposition gene mutations but most are unaware.

Tempus AI (NASDAQ: TEM), a technology company focused on advancing precision medicine through AI, announced its participation in TD Cowen's 4th Annual Tools/Dx Revolution Conference. The event will be held from June 22-25, 2025, in Dana Point, California. Jim Rogers, Tempus's Chief Financial Officer, will be a panelist in the session titled 'Acing AI – How To Play The Platforms' scheduled for June 23. The conference serves as a platform for discussing innovations in diagnostic tools and technologies.

Tempus AI (NASDAQ: TEM) has announced a strategic collaboration with Northwestern University's Abrams Research Center on Neurogenomics to advance Alzheimer's disease research using artificial intelligence. The partnership will utilize Tempus' AI-powered data analytics platform, Lens, to analyze and restructure the Center's genomic data repository. The multi-year collaboration aims to uncover genomic patterns, investigate affected genes and cell types, enable new therapeutic development, and accelerate clinical applications. The initiative brings together Tempus' advanced AI capabilities with the Center's neurogenomics expertise to drive targeted therapy discovery and improve patient outcomes for those affected by Alzheimer's disease.

Tempus AI (NASDAQ: TEM) has unveiled xM for treatment response monitoring (TRM), a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor therapy in advanced solid tumors. The assay, currently available for research use only with clinical availability expected later in 2025, monitors circulating tumor DNA (ctDNA) changes from blood samples to assess early molecular response in patients receiving immunotherapy. The technology utilizes a multi-parametric algorithm that integrates copy number variations and variant allele frequencies for comprehensive tumor fraction estimation. According to 2023 data, while 56.55% of advanced cancer patients were eligible for immune-checkpoint inhibitors, only 20.13% showed response. Tempus is presenting new data at the 2025 ASCO Annual Meeting, demonstrating how xM for TRM can detect molecular response within six weeks of treatment initiation, potentially enabling clinicians to optimize therapeutic strategies earlier.

Tempus AI (NASDAQ: TEM) has announced significant enhancements to Tempus One, its generative AI clinical assistant, by integrating it directly with electronic health record (EHR) systems. The expanded platform now incorporates ASCO clinical practice guidelines and features comprehensive workflow assistance tools. Key capabilities include pre-appointment preparation, real-time support during patient visits, and post-appointment documentation assistance. The system can analyze patient data, transcribe conversations, and facilitate clinical trial matching. Through its Agent Builder GenAI tool, Tempus has developed over 1,000 AI agents and is now extending this capability to select healthcare partners for custom solution development. The platform leverages Tempus's extensive EHR integrations across the U.S., accessing real-time clinical, molecular, and imaging data from millions of patients to streamline physician workflows and enhance treatment decisions.

Tempus AI (NASDAQ: TEM) has launched its Fuses program, leveraging its extensive multimodal dataset to develop AI-enabled diagnostic platforms for precision medicine. The company's data library includes over 40 million research records, featuring 1.5 million records with matched clinical-genomic data, 2 million imaging records, and 300,000 records with genomic and transcriptomic data. The program builds on Tempus' earlier success with its Immune Profile Score (IPS) for metastatic pan-solid tumors. Fuses aims to develop clinically validated algorithmic diagnostics to enable personalized patient care, identify treatment responses, and predict adverse events. The foundational model will help understand clinical trial failures, identify new drug indications, optimize trial design, and uncover combination therapies.